AgomAb Therapeutics NV
Research AgomAb Therapeutics NV (AGMB) on Bullrun: market cap USD 690.46M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAGMB
- ExchangeNASDAQ
- CountryBelgium
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 690.46M
- Financial periodQ2 2026
Valuation Snapshot
latest market cap is USD 690.46M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 690.46M | n/a | n/a | n/a |
About AgomAb Therapeutics NV
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AgomAb Therapeutics NV's market cap?
AgomAb Therapeutics NV's market capitalization is USD 690.46M.
What does AgomAb Therapeutics NV do?
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.